Trial Profile
Safety and efficacy of rituximab in patients with refractory myositis and overlap myositis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2014
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Autoimmune disorders
- Focus Therapeutic Use
- 17 Oct 2014 New trial record